Stéphane Bancel, Moderna CEO (Photo by Fabrice Coffrini/AFP via Getty Images)
November 3, 2022 01:25 PM EDTUpdated 02:22 PM
Pharma

Mod­er­na's stock plunges in pre­mar­ket trad­ing as Ban­cel promis­es com­pa­ny is in 'much bet­ter place' for FY23 de­liv­er­ies

Nicole DeFeudis

Editor

Mod­er­na’s stock plunged more than 11% in pre­mar­ket trad­ing on Thurs­day as CEO Stéphane Ban­cel re­port­ed a drop in Covid sales and low­ered his full …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Te­va’s MS drug and gener­ics to add black box warn­ing for ana­phy­lax­is

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times